As the HGF/MET signaling pathway plays a role in several key processes underlying tumor progression, targeting this pathway is considered a promising therapeutic strategy for the treatment of patients with MET-expressing cancers, including those with NSCLC who have acquired resistance to EGFR TKIs. The gene discussed is HGF; the disease is non-small cell lung carcinoma.